2 Anti-Kickback Developments Hold Lessons For Biopharma

By Mary Kohler · February 13, 2025, 6:25 PM EST

Last year ushered in new Anti-Kickback Statute concerns for biopharma companies after Ultragenyx Pharmaceutical Inc. paid $6 million to settle U.S. Department of Justice allegations about its free genetic testing program...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Settlement
Advisory Opinion

Related Sections

Healthcare Authority Policy & Compliance

Already have access? Click here to login

Get instant access to the one-stop news source for business lawyers

Sign up now for free access to this content

Email (NOTE: Free email domains not supported)

First Name

Last Name

Phone Number (###-###-####)

PLEASE NOTE: A verification email will be sent to your address before you can access your trial.

Password (at least 8 characters required)

Confirm Password

Job Title

Select at least one primary interest:

Healthcare Authority

Law360 Healthcare Authority may contact you in your professional capacity with information about our other products, services and events that we believe may be of interest.

You’ll be able to update your communication preferences via the unsubscribe link provided within our communications.

We take your privacy seriously. Please see our Privacy Policy.

Start Reading

Already have access?

Email:
Password: Forgot your password?
Remember login
Sign In

Sign up for our Healthcare Authority newsletter

You must correct or enter the following before you can sign up:

Please provide a professional email:

Healthcare Authority

Law360 Healthcare Authority takes your privacy seriously. Please see our Privacy Policy.